IFNG and non-small cell lung carcinoma: For instance, in tumour types (such as skin melanoma, breast, NSCLC, bladder and thymus) where IP expression was associated with better prognosis and response to ICB therapies, immunoproteasome activators (IFN‐γ or 5‐aza‐dC) or others to enhance interferon signalling can be combined with ICB therapies [13].